BE1000587A4 - Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. - Google Patents

Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. Download PDF

Info

Publication number
BE1000587A4
BE1000587A4 BE8700641A BE8700641A BE1000587A4 BE 1000587 A4 BE1000587 A4 BE 1000587A4 BE 8700641 A BE8700641 A BE 8700641A BE 8700641 A BE8700641 A BE 8700641A BE 1000587 A4 BE1000587 A4 BE 1000587A4
Authority
BE
Belgium
Prior art keywords
sep
lymphocytes
cells
fab
compound
Prior art date
Application number
BE8700641A
Other languages
English (en)
French (fr)
Inventor
Jeffrey A Ledbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Application granted granted Critical
Publication of BE1000587A4 publication Critical patent/BE1000587A4/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BE8700641A 1986-06-13 1987-06-10 Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. BE1000587A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (1)

Publication Number Publication Date
BE1000587A4 true BE1000587A4 (fr) 1989-02-14

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700641A BE1000587A4 (fr) 1986-06-13 1987-06-10 Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.

Country Status (22)

Country Link
JP (1) JPH0762040B2 (ja)
KR (1) KR910004100B1 (ja)
AT (1) AT398437B (ja)
AU (1) AU617087B2 (ja)
BE (1) BE1000587A4 (ja)
CA (1) CA1338781C (ja)
CH (1) CH676600A5 (ja)
CY (1) CY1681A (ja)
DE (1) DE3719398C2 (ja)
DK (1) DK173940B1 (ja)
FR (1) FR2607136B1 (ja)
GB (1) GB2191494B (ja)
GR (1) GR870930B (ja)
HK (1) HK10293A (ja)
IE (1) IE60486B1 (ja)
IL (1) IL82841A (ja)
IT (1) IT1208649B (ja)
LU (1) LU86919A1 (ja)
NL (1) NL195022C (ja)
PT (1) PT85073B (ja)
SE (1) SE504675C2 (ja)
SG (1) SG118992G (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
PROC. NATL. ACAD. SCI. USA, vol. 79, octobre 1982, page 5998-6002, Washington, US; A. MAIZEL et al.: "Biochemical separation of a human B cell mitogenic factor" *
PROC. NATL. ACAD. SCI. USA, vol. 82, mars 1985, pages 1766-1770, Washington, US; E.A. CLARK et al.: "Role of the Bp35 cell surface polypeptide in human B-cell activation" *
PROC. NATL. ACAD. SCI. USA, vol. 83, no. 12, juin 1986, pages 4494-4498, Washington, US; E.A. CLARK et al.: "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50" *
THE JOURNAL OF IMMUNOLOGISTS, vol. 138, no. 3, février 1987, pages 788-794, The American Association of Immunologists, Baltimore, US; J.A. LEDBETTER et al.: "Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40)" *
THE JOURNAL OF IMMUNOLOGY, vol. 133, no. 2, août 1984, pages 684-691, The American Association of Immunologists, Baltimore, US; C.Y. WANG et al.: "Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes" *

Also Published As

Publication number Publication date
IE871563L (en) 1987-12-13
PT85073A (en) 1987-07-01
FR2607136B1 (fr) 1989-09-15
IL82841A0 (en) 1987-12-20
GB8713650D0 (en) 1987-07-15
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
JPH0762040B2 (ja) 1995-07-05
CA1338781C (en) 1996-12-10
DE3719398C2 (de) 1996-03-28
AU617087B2 (en) 1991-11-21
SE8702463L (sv) 1987-12-14
JPS6480299A (en) 1989-03-27
AU7421487A (en) 1987-12-17
SE504675C2 (sv) 1997-04-07
IT8720899A0 (it) 1987-06-12
NL8701371A (nl) 1988-01-04
LU86919A1 (fr) 1989-03-08
DE3719398A1 (de) 1988-01-28
KR910004100B1 (ko) 1991-06-22
SG118992G (en) 1993-01-29
IE60486B1 (en) 1994-07-27
GB2191494A (en) 1987-12-16
IL82841A (en) 1992-11-15
AT398437B (de) 1994-12-27
GB2191494B (en) 1990-08-22
IT1208649B (it) 1989-07-10
KR880000582A (ko) 1988-03-28
GR870930B (en) 1987-12-16
PT85073B (pt) 1990-07-31
SE8702463D0 (sv) 1987-06-12
CH676600A5 (ja) 1991-02-15
HK10293A (en) 1993-02-19
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
FR2607136A1 (fr) 1988-05-27
DK302287A (da) 1987-12-14

Similar Documents

Publication Publication Date Title
CA1183470A (en) Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods
FI75183B (fi) Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje.
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
US5786456A (en) Bp 50-specific antibodies and fragments thereof
FI75184B (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot maenskliga t-cellers antigener med en ny hybridcellinje.
FI75362C (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot maenniskans t-celler, medelst en ny hybridcellinje.
CN101970478A (zh) 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物
EP0287615A1 (en) (ex vivo)-effector cell activation for target cell killing
JPH05268986A (ja) モノクローナル抗体及びリンパ球の活性法
JPH0159872B2 (ja)
CA1175367A (en) Hubrid cell line for producing monoclonal antibody to a human early thymocyte antigen, antibody, and methods
IE50672B1 (en) Hybrid cell line for producing monoclonal antibody to human thymocyte antigen,antibody,method of preparation of this antibody,diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
BE1000587A4 (fr) Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
WO1991012332A1 (fr) Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
CA1270778A (fr) Cellules hybrides secretant des anticorps anti- idiotypiques, anticorps monoclonaux secretes par lesdites cellules hybrides, leur preparation et leur application
US4624925A (en) Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigens, antibody, and methods
JPH0216978A (ja) 白血球の活性化を監視するためのモノクローナル抗体
Levine et al. Differential modulation of the CD-2 and CD-3 T cell activation pathways by a monoclonal antibody to Leu-13
Umezawa et al. Identity of brain-associated small cell lung cancer antigen and the CD56 (NKH-1/Leu-19) leukocyte differentiation antigen and the neural cell adhesion molecule
WO1991000921A1 (fr) Fragments d'anticorps monoclonaux specifiques de la presence de leucocytes actives - leur procede d'obtention et leur application dans le cas de rejet de greffe
Brendel et al. 7th Round Table Symposium on Applied Immunology
FR2672615A1 (fr) Anticorps monoclonal dirige contre des recepteurs de cellules t humaines a chaines gamma.
SI8013066A8 (sl) Postopek za pripravo monoklonalnega protitelesa okt6
HRP940809A2 (en) Hybrid cell line for producing complement-fixing monoclonal antibody to human t cells, antibody and methods
HRP940824A2 (en) Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *ONCOGEN

Effective date: 20070610